Latest Pseudomonas infection Stories
DNA from cystic fibrosis patients with and without chronic infections points to unsuspected mutation
Researchers at Brigham and Women's Hospital (BWH) have discovered a new vaccine candidate for the bacterium Pseudomonas aeruginosa taking advantage of a new mechanism of immunity.
Patients with chronic obstructive pulmonary disease (COPD) who become infected with the bacterium Pseudomonas aerguinosa are more likely to have worse clinical outcomes and experience more hospitalizations during the course of their disease than COPD patients who are not infected, according to researchers from Buffalo, N.Y.
MONMOUTH JUNCTION, N.J., June 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACEÂ® (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections.
VIENNA, April 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients.
The bacterium, called Pseudomonas aeruginosa, is the most common cause of persistent and fatal lung infections in cystic fibrosis patients.
New research in the Journal of Leukocyte Biology shows that glycyrrhizin extracted from licorice root helps the body defend against Pseudomonas aeruginosa infection.
Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment of Pseudomonas Lung Infections MONMOUTH JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, has provided a $2.2 million award to Transave Inc., for the continued development of ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat Pseudomonas lung infections in cystic fibrosis (CF) and non-CF...
ZURICH, Switzerland, April 30 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.